MiNK Therapeutics (INKT) Total Non-Current Liabilities (2020 - 2026)

MiNK Therapeutics (INKT) posted Total Non-Current Liabilities of $10.1 million for Q1 2026, up 76.43% sequentially from $5.7 million in Q4 2024.

MiNK Therapeutics (INKT) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

MiNK Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $10.1 million in Q1 2026.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (changed N/A YoY) and the FY2024 annual result came in at $5.7 million, up 27.01% from the prior year.
Total Non-Current Liabilities advanced to $10.1 million in Q1 2026 per INKT's latest filing, from $5.7 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $25.2 million in Q3 2022 and troughed at $4.5 million in Q4 2023.
A 4-year average of $11.6 million and a median of $10.1 million in 2026 frame the typical range for Total Non-Current Liabilities.
The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 522.33% in 2022, then tumbled 78.92% in 2023.
Over 4 years, Total Non-Current Liabilities stood at $21.4 million in 2022, then sank by 78.92% to $4.5 million in 2023, then gained by 27.01% to $5.7 million in 2024, then soared by 76.43% to $10.1 million in 2026.
According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.1 million, $5.7 million, and $7.4 million for Q1 2026, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	140.23 Bn	132.38 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	86.97 Bn	78.97 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	40.00 Mn
4	Moderna	59.88 Bn	54.74 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	42.20 Bn	37.11 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	4.20 Bn
7	BioNTech SE	28.69 Bn	10.30 Bn	668.28 Mn	724.15 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	1.17 Bn
9	Royalty Pharma	27.16 Bn	26.33 Bn	-	9.32 Bn
10	MiNK Therapeutics	56.36 Mn	56.36 Mn	-	9.59 Mn

Download Data